PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Amla supplementation is associated with a reduction in LDL-cholesterol and improvement in HDL-cholesterol levels [PMID:31890983]. A meta-analysis of RCTs examined its effects on lipid profiles and glucose [PMID:36934568].
Supplementation with Amla extract for 4 months reduced the plasma oxidative marker 8-iso-prostaglandin and increased total antioxidant status (TAS) [PMID:19222108].
Aqueous extract (20 mg/kg) in HFD-induced obese rats resulted in significant reduction in body weight gain and insulin [PMID:29206643].
Amla powder (5-7% of diet) improved body weight, controlled kidney hypertrophy, and reduced blood glucose [PMID:40734446].
Administration of amla reduced serum creatinine, urea nitrogen, and systolic blood pressure in aged rats [PMID:17715896].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 26448818 (2015) — Anti-Aging Potential of Phytoextract Loaded-Pharmaceutical Creams for Human Skin Cell Longetivity. · Oxidative medicine and cellular longevity
- 2.PMID: 34480995 (2022) — Traditional uses, bioactive composition, pharmacology, and toxicology of Phyllanthus emblica fruits: A comprehensive review. · Journal of ethnopharmacology
- 3.PMID: 27320046 (2016) — Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. · Pharmacological research
- 4.PMID: 21317655 (2011) — Amla (Emblica officinalis Gaertn), a wonder berry in the treatment and prevention of cancer. · European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
- 5.PMID: 29206643